Aileron Therapeutics to Present at Upcoming H.C. Wainwright Virtual Global Investment Conference

Rhea-AI Summary

Aileron Therapeutics (NASDAQ: ALRN) announced a corporate presentation by CEO Manuel Aivado at the H.C. Wainwright Virtual Global Investment Conference on September 14, 2020, at 2:00 PM ET. The presentation will cover advancements in chemoprotection for patients with p53-mutated cancers, regardless of cancer type or chemotherapy. A live webcast will be available on Aileron's website, with a replay archived for 30 days. The company focuses on ALRN-6924, a dual MDM2/MDMX inhibitor aimed at improving chemotherapy outcomes and reducing side effects for around 50% of cancer patients.

WATERTOWN, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation at the upcoming H.C. Wainwright Virtual Global Investment Conference, including an update on the company’s efforts to advance chemoprotection for patients with p53-mutated cancers regardless of cancer type or chemotherapeutic drug.

The presentation is scheduled for September 14, 2020 at 02:00 pm ET.  

A live webcast of the presentation will be available under the Investors and Media section of Aileron’s website at https://investors.aileronrx.com/. A replay of the live webcast will be archived on Aileron’s website for 30 days following the event.

About Aileron Therapeutics

At Aileron, we are focused on transforming the experience of chemotherapy for cancer patients, enabling them to fight cancer without the fear or burden of chemotherapy-induced side effects. We are advancing ALRN-6924, our first-in-class dual MDM2/MDMX inhibitor that activates wild-type p53.  ALRN-6924 is in clinical development to provide a single medicine to protect multiple healthy cell types throughout the body from chemotherapy while ensuring chemotherapy continues to destroy cancer cells. In addition to potentially reducing or eliminating multiple side effects, ALRN-6924 may also improve patients’ quality of life and help them better tolerate chemotherapy, thereby allowing patients to complete their treatment without dose reductions or delays. Our long-term vision is to provide chemoprotection for patients with p53-mutated cancers, which represent approximately 50% of cancer patients, regardless of cancer type or chemotherapeutic drug. Visit us at aileronrx.com to learn more.

Investor Contacts:

Aileron Therapeutics
Richard Wanstall, SVP Chief Financial Officer
617-995-0900
rwanstall@aileronrx.com

Hans C. Vitzthum
LifeSci Advisors, LLC.
617-430-7578
hans@lifesciadvisors.com

Media Contact:
Liz Melone
617-256-6622
lmelone@aileronrx.com

FAQ

What is the date of Aileron Therapeutics' presentation at the H.C. Wainwright Virtual Global Investment Conference?

The presentation is scheduled for September 14, 2020, at 2:00 PM ET.

Who will present for Aileron Therapeutics at the investment conference?

Manuel Aivado, M.D., Ph.D., President and CEO, will give the presentation.

What is the focus of Aileron Therapeutics' upcoming presentation?

The presentation will focus on chemoprotection for patients with p53-mutated cancers.

How can I watch Aileron Therapeutics' presentation online?

A live webcast will be available on Aileron's website under the Investors and Media section.

What is ALRN-6924 and its significance for cancer patients?

ALRN-6924 is a first-in-class dual MDM2/MDMX inhibitor that aims to protect healthy cells during chemotherapy and improve patient quality of life.